TAC chemotherapy improves relapse-free survival in certain early breast cancer subtypes
Doctors found that certain tumor markers might help choose the best cancer treatment plan for some patients
A randomized trial compared TAC to ddAC in early breast cancer. The authors observed improved relapse-free survival in specific tumor subtyp…
This study looked at how two different drug schedules worked for people with early breast cancer. Results suggest that specific tumor featur…
Neoadjuvant ICI plus chemotherapy improves event-free survival in early-stage TNBC
Adding immune drugs to chemo helps early stage triple negative breast cancer patients stay disease free longer
A meta-analysis found neoadjuvant immune checkpoint inhibitors with chemotherapy significantly improved event-free survival but not overall …
A large review of trials found that adding immune checkpoint inhibitors to chemotherapy improves survival chances for early stage triple neg…
CPX-351 improves survival in AML with myelodysplasia-related changes
New leukemia treatment works best for specific gene type
This randomized phase 3 trial in 184 patients with AML and myelodysplasia-related mutations evaluated CPX-351 versus standard cytarabine plu…
A leukemia drug thought to help many patients actually works only in those with a specific genetic subtype, leaving others in need of better…
Histology-derived gene-expression signatures predict distant recurrence-free interval and chemotherapy benefit in early breast cancer cohorts
New Tool Predicts Breast Cancer Recurrence From Old Slides
This multi-cohort study evaluated histology-derived gene-expression signatures from routine hematoxylin and eosin slides compared with clini…
A simple AI analysis of old biopsy slides can now predict which breast cancer patients face higher risk of recurrence and who truly benefits…